Candel Therapeutics (CADL)
NASDAQ:CADL
Top Page
Candel Therapeutics
(NASDAQ:CADL)
Select Model
Select Model
Rating:47Neutral
Price Target:
$5.00
▲(0.40% Upside)
Action:ReiteratedDate:03/13/26
The score is held down primarily by weak financial performance (minimal revenue, ongoing losses, and sustained cash burn) and bearish-to-neutral technical momentum (below key moving averages with negative MACD). Positive financing events improve funding runway and balance-sheet flexibility, but they do not fully offset the current lack of operating profitability and negative cash flow.
Positive Factors
Extended cash runway into Q1 2028
Having cash and expected proceeds that extend runway into Q1 2028 materially lowers near-term financing pressure and gives management time to complete pivotal readouts, a BLA submission, and pre-commercial activities. This durable liquidity supports execution of multi-quarter clinical and launch milestones.
Negative Factors
Effectively zero revenue and persistent operating losses
With no meaningful product revenue and large recurring operating losses, the company cannot internally fund development or commercialization. This structural lack of operating income forces reliance on external capital and magnifies downside if clinical or regulatory setbacks occur.
Read all positive and negative factors
Positive Factors
Negative Factors
Extended cash runway into Q1 2028
Having cash and expected proceeds that extend runway into Q1 2028 materially lowers near-term financing pressure and gives management time to complete pivotal readouts, a BLA submission, and pre-commercial activities. This durable liquidity supports execution of multi-quarter clinical and launch milestones.
Read all positive factors
Candel Therapeutics (CADL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$364.77M
Dividend YieldN/A
Average Volume (3M)1.58M
Price to Earnings (P/E)―
Beta (1Y)0.53
Revenue GrowthN/A
EPS Growth68.53%
CountryUS
Employees38
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.54
Shares Outstanding73,246,925
10 Day Avg. Volume1,178,491
30 Day Avg. Volume1,578,788
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)5.76
Price to Sales (P/S)0.00
P/FCF Ratio-7.69
Enterprise Value/Market Cap0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-185.42
Enterprise Value/Ebitda-3.30
Forecast
1Y Price Target
$19.40Price Target Upside289.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.26
Revenue Forecast (FY)N/A
Candel Therapeutics Business Overview & Revenue Model
Company Description
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; ...
How the Company Makes Money
As a clinical-stage biotechnology company, Candel Therapeutics does not have publicly established recurring product sales from approved therapies; therefore, revenue is not primarily generated from commercialized drugs (null). The company’s fundin...
Candel Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
58
Neutral
Cash Flow
29
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 125.00K | 125.00K |
| Gross Profit | -845.00K | -990.00K | -23.98M | 125.00K | -14.47M |
| EBITDA | -47.42M | -52.10M | -37.43M | -16.31M | -25.49M |
| Net Income | -38.18M | -55.18M | -37.94M | -18.79M | -36.12M |
Balance Sheet | |||||
| Total Assets | 125.19M | 106.87M | 41.20M | 78.52M | 89.20M |
| Cash, Cash Equivalents and Short-Term Investments | 119.73M | 102.65M | 35.41M | 70.06M | 82.64M |
| Total Debt | 1.90M | 13.47M | 22.76M | 22.80M | 560.00K |
| Total Liabilities | 73.27M | 40.54M | 28.46M | 30.80M | 25.07M |
| Stockholders Equity | 51.92M | 66.33M | 12.74M | 47.71M | 64.14M |
Cash Flow | |||||
| Free Cash Flow | -38.90M | -27.04M | -34.70M | -32.72M | -24.05M |
| Operating Cash Flow | -38.31M | -27.02M | -34.24M | -31.42M | -22.22M |
| Investing Cash Flow | -560.00K | -16.00K | -280.00K | -1.30M | -1.83M |
| Financing Cash Flow | 56.10M | 94.28M | -121.00K | 19.97M | 71.80M |
Candel Therapeutics Technical Analysis
Neutral
4.98
Price Trends
5.34
Negative
5.36
Negative
5.50
Negative
Market Momentum
-0.13
Negative
48.88
Neutral
47.37
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CADL, the sentiment is Neutral. The current price of 4.98 is above the 20-day moving average (MA) of 4.93, below the 50-day MA of 5.34, and below the 200-day MA of 5.50, indicating a neutral trend. The MACD of -0.13 indicates Negative momentum. The RSI at 48.88 is Neutral, neither overbought nor oversold. The STOCH value of 47.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CADL.
Candel Therapeutics Risk Analysis
Candel Therapeutics disclosed 91 risk factors in its most recent earnings report. Candel Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Candel Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $1.37B | ― | -15.12% | ― | 1112.27% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $364.77M | -7.84 | -51.44% | ― | ― | 68.53% | |
46 Neutral | $161.76M | -2.15 | -43.90% | ― | 40.20% | -4.07% | |
44 Neutral | $183.39M | -0.71 | -60.15% | ― | -8.79% | 81.36% | |
44 Neutral | $131.41M | -3.72 | -424.76% | ― | ― | 82.23% | |
42 Neutral | $979.40M | ― | -269.56% | ― | ― | ― |
* Healthcare Sector Average
CADL
Candel Therapeutics
4.98
-0.27
-5.14%
TNXP
Tonix Pharma
13.68
-3.81
-21.78%
QSI
Quantum-Si
0.75
-0.41
-35.60%
HUMA
Humacyte
0.59
-0.86
-59.24%
GLUE
Monte Rosa Therapeutics
17.17
13.28
341.39%
INBX
Inhibrx Biosciences Inc
67.05
53.72
403.00%
Candel Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Candel Therapeutics Announces Equity Offering to Fund CAN-2409
Positive
Feb 23, 2026
On February 19, 2026, Candel Therapeutics, Inc. entered into an underwriting agreement to sell 18,348,624 shares of common stock at $5.45 per share, with underwriters granted a 30-day option to buy up to an additional 2,752,293 shares. The registe...
Business Operations and StrategyPrivate Placements and Financing
Candel Therapeutics Secures $100M Royalty Funding for CAN-2409
Positive
Feb 19, 2026
On February 19, 2026, Candel Therapeutics announced a $100 million royalty-based funding agreement with funds managed by RTW Investments to support the potential U.S. launch of its lead candidate aglatimagene besadenovec for intermediate- to high-...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.